Clinical Trials Logo

Skin Squamous Cell Carcinoma clinical trials

View clinical trials related to Skin Squamous Cell Carcinoma.

Filter by:

NCT ID: NCT06223659 Recruiting - Clinical trials for Merkel Cell Carcinoma

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Start date: December 19, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well EMLA topical cream works in treating pain in patients with skin cancers receiving Technetium 99 injections for a lymphoscintigraphy mapping procedure. A lymphoscintigraphy mapping procedure is used to find the main or lead lymph node (tissue that fight infection) so it can be removed and checked for tumor cells. Using lymphoscintigraphy to highlight and then surgically remove lymph nodes is standard way to treat skin cancer for many patients. The Technetium 99 injections used for lymphoscintigraphy can be briefly painful due to the sensitivity of the nerve endings in the skin. The EMLA topical cream, which contains a numbing medicine to block pain from nerve endings, has been studied in breast cancer patients with a difference in pain reported, but this is the first time it has been studied in patients undergoing lymphoscintigraphy for skin cancer. This study may help researchers learn whether the use of EMLA cream may improve the associated pain at the time of the lymphoscintigraphy procedure.

NCT ID: NCT05269381 Recruiting - Metastatic Melanoma Clinical Trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

PNeoVCA
Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.

NCT ID: NCT04234113 Active, not recruiting - Ovarian Cancer Clinical Trials

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Start date: June 13, 2019
Phase: Phase 1
Study type: Interventional

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors

NCT ID: NCT03944941 Active, not recruiting - Clinical trials for Skin Squamous Cell Carcinoma

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Start date: May 17, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03822988 Recruiting - Melanoma Clinical Trials

ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

PADAONCODERM
Start date: January 21, 2019
Phase:
Study type: Observational

The law about advance directives is evolving but, in France, few people write it. Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic. Seconds endpoints are : For patients against or not planning to write it, understand their reasons Estimate the proportion of patients requesting information and understand how they would like to receive it. Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.

NCT ID: NCT03353077 Completed - Clinical trials for Skin Squamous Cell Carcinoma

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)

Start date: November 21, 2017
Phase: N/A
Study type: Interventional

A unique approach for Skin Squamous Cell Carcinoma (SCC) treatment employing intratumoral diffusing alpha radiation emitter device

NCT ID: NCT03108131 Active, not recruiting - Clinical trials for Locally Advanced Malignant Neoplasm

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.

NCT ID: NCT02978625 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.

NCT ID: NCT02964559 Active, not recruiting - Clinical trials for Skin Squamous Cell Carcinoma

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Start date: January 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT01807546 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Oral Rigosertib for Squamous Cell Carcinoma

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects. Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.